anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Monitor renal function periodically in patients treated with ATACAND. Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system. Patients whose renal function may depend, in part, on the activity of the renin-angiotensin system (e.g., patient with renal artery stenosis, chronic kidney disease, severe heart failure, or volume depletion) may be at particular risk of developing oliguria, progressive azotemia or acute renal failure when treated with ATACAND. Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function on ATACAND.

In the CHARM program (heart failure patients), the incidence of abnormal renal function (e.g., creatinine increase) was 12.5% in patients treated with ATACAND versus 6.3% in patients treated with placebo. The incidence of abnormal renal function (e.g., creatinine increase) leading to drug discontinuation in ATACAND-treated patients was 6.3% compared with 2.9% in placebo-treated patients. In the CHARM-Added program, where candesartan or placebo was given in addition to ACE inhibitors, the incidence of abnormal renal function (e.g., creatinine increase) was 15% in patients treated with ATACAND versus 9% in patients treated with placebo [see Drug Interactions (7.3)].
The invention provides a Chinese herbal medicine health care cushion and a preparation method thereof, belonging to the health care product technical field. The invention solves the problems that the compatibility of herbal medicine components of the medicine cushion is not reasonable, the function of enhancing medicine can not be given full play, the function effect is light, and etc. The herbal medicine health care cushion includes an outer casing and a medicine bag. The medicine bag is arranged in the outer casing. The medicine bag is infiltrated or filled with the Chinese herbal components with the following portions of 5 to 30 portions of white ginseng, 10 to 30 portions of astragulus, 10 to 30 portions of angelica sinensis, 10 to 30 portions of white peony root, 5 to 20 portions of rhizomaligust, 5 to 30 portions of green garden burnet, 10 to 30 portions of desertliving cistanche, 10 to 30 portions of Chinese dwarf cherry seed and 5 to 30 portions of senna leaf. The preparation method of the Chinese herbal medicine health care cushion includes two steps of grinding and assembling. The Chinese herbal medicine health cushion of the invention is provided with the functions of supplementing qi, de-emphasis, stimulating circulation to end stasis and nourish blood, moistening, etc.
The present invention provides isolated peptides of the major protein allergens of the genus Dermatophagoides. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen selected from the allergens Der p I, Der p II, Der .function. I, or Der .function. II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having seduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or of diagnosis of sensitivity to house dust mites in an individual and therapeutic compositions comprising one or more peptides of the invention are also provided.
A fusion protein comprising: a first cytokine that is a mutated variant of IL-13 (interleukin 13); a second cytokine that is a mutated variant of IL-4, IL-10, IL-13, IL-33, IL-27, TGFβ1, or TGFβ2; and a peptide linker. The peptide linker may be a flexible peptide linker that is joined to the first cytokine at the N terminus and joined to the second cytokine that is joined at the C terminus, or vice versa. The fusion protein may be IL-13/IL-4, IL-13/IL-10, IL-13/IL-13, IL-13/IL-33, IL-13/IL-27, IL-13/TGFβ1 or IL-13/TGFβ2. The fusion/chimeric/hybrid protein may also comprise chemical modifications, such as glycosylation, fucosylation, sialylation, or pegylation. Also claimed is a pharmaceutical composition comprising the fusion protein, a nucleic acid molecule comprising a sequence encoding the fusion protein, and a vector comprising the nucleic acid. The fusion protein may be for use in treating inflammation, pain, neuropathy, peripheral neuropathy, chemotherapy-induced neuropathy, or neurodegeneration.
This group received cyclosporin intravenously 2 hours pre-induction of anesthesia, with the dose of 3 mg/ kg body weight. RIPC was performed preoperatively after induction of anesthesia by inflating pressure cuff on the extremity 30 mmHg higher than systolic blood pressure of the patient for 5x5 minutes with 5 minutes reperfusion interval.
Subclinical sleep dysfunction has a multitude of causes (e.g., environmental, cognitive, behavioral, or physiological) and symptoms (e.g., long sleep onset latency, short sleep duration, elevated wake after sleep onset and nighttime awakenings, poor sleep quality). A personalized and dynamic sleep improvement intervention tailored to an individual's lifestyle and specific needs may therefore be required to help nudge those with poor sleep towards sleep-promoting behaviors and attitudes. Digital and mobile health platforms are also highly scalable and cost-effective, thus allowing for widespread implementation across larger subclinical populations.

The purpose of the present study is to conduct a single-blinded randomized waitlist controlled trial to evaluate a novel smartphone application, Dein Schlaf. Dein Tag. powered by SleepScore, designed to both objectively measure and improve sleep. The Dein Schlaf. Dein Tag. app features a validated sonar sleep measurement tool and also provides dynamic and personalized sleep advice founded in the principles of cognitive behavioral psychology and sleep hygiene, offering a non-invasive and non-pharmacological behavioral intervention designed to improve sleep and circadian functioning in those with common sleeping difficulties. Participants will be randomly assigned to the sleep improvement app intervention or a waitlist control group. Online assessments on validated sleep and preventative health measures will take place at baseline, 6 weeks, and 12 weeks.
Subjects will receive matching placebo on Day 1. This will be administered under fed conditions with a standard meal, according to the randomization schedule.
INTRODUCTION: Acute myocardial infarction (AMI) is a serious, deadly disease with a high incidence. However, it remains unclear how necroptosis affects the pathophysiology of AMI. Using bioinformatic analyses, this study investigated necroptosis in AMI.
METHODS: We obtained the GSE66360 dataset related to AMI by the GEO database. Venn diagrams were used to identify necroptosis-related differential genes (NRDEGs). The genes with differential expression in AMI were analyzed using gene set enrichment analysis, and a PPI network was established. A transcription factor prediction and enrichment analysis were conducted for the NRDEGs, and the relationships between AMI, NRDEGs, and immune cells were determined. Finally, in the additional dataset, NRDEG expression levels, immune infiltration, and ROC curve analysis were confirmed, and gene expression levels were further verified experimentally.
RESULTS: GSEA revealed that necroptosis pathways were significantly enriched in AMI. We identified 10 NRDEGs, including TNF, TLR4, FTH1 and so on. Enrichment analysis indicated that the NOD-like receptor and NF-kappa B signaling pathways were significantly enriched. Four NRDEGs, FTH1, IFNGR1, STAT3, and TLR4, were identified; however, additional datasets and further experimental validation are required to confirm their roles. In addition, we determined that a high abundance of macrophages and neutrophils prompted AMI development.
CONCLUSIONS: In this study, four potential genes that affect the development of AMI through necroptosis (FTH1, IFNGR1, STAT3, and TLR4) were identified. In addition, we found that a high abundance of macrophages and neutrophils affected AMI. This helps determine the pathological mechanism of necroptosis and immune cells that influence AMI and provides a novel strategy for targeted therapy.
The present invention provides a system, method and apparatus for targeting gene sequences having one or more phenotypic characteristics using a computer.  One or more phenotypic characteristics are selected. A gene sequence is then selected that is known to have the selected phenotypic characteristics. In addition, one or more databases containing cataloged gene sequences are selected. The selected gene sequence is compared to the cataloged gene sequences, and any cataloged gene sequences that contain a portion of the selected gene sequence are extracted. The selected gene sequence is aligned to each portion of the extracted gene sequence and the extracted gene sequences are prioritized based on the alignment of the selected gene sequence. At least one of the prioritized gene sequences is selected based on one or more phenotypic criteria. Finally, one or more degenerate primers are designed to target the selected-prioritized gene sequences.
This is an open-label (all people know the identity of the intervention) study. A total of 35 participants will be enrolled in this study. Participants will receive tablet of combination of tramadol HCI (37.5 mg)/acetaminophen (325 mg) on Day 1. Participants may increase their daily dosage of study medication as 1 to 2 tablets every 4 to 6 hours as needed for pain relief, up to maximum of 8 tablets per day. Rescue medication consisting of Extra Strength Tylenol (500 mg) 2 tablets daily for the first six days of the Open-label Phase will be allowed so that the total daily dose of acetaminophen will not exceed 4,000 mg. The total duration of the study treatment for each participant will be approximately 6 weeks. Safety will be evaluated by assessment of adverse events, clinical laboratory tests, skin site assessments, vital signs, and physical examination which will be monitored throughout the study.
Central nervous system (CNS) infection is one of the important risk factors for epilepsy. COVID-19 pandemic, which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has primarily been considered to involve respiratory system only, but it can also affect the CNS. A wide range of neurological manifestations have been reported in SARS-CoV-2 infected patients including seizures, status epilepticus, stroke, which are considered as important risk factors for the development of epilepsy. In post-mortem, brain tissue samples of COVID-19 patients have shown neuropathological changes and presence of SARS-CoV-2 RNA and viral proteins. In this review, mechanisms of SARS-CoV-2 neuroinvasion like neuronal retrograde trans-synaptic route and vascular route are described along with important neurological manifestations in COVID-19 patients such as seizures and cerebrovascular diseases, which have been found to be associated with the development of epilepsy. Hence, an increased risk of future burden of epilepsy in susceptible COVID-19 survivors has been proposed and preventive measures are suggested. The present review highlights about the possible association between neurological manifestations and future risk of epilepsy in COVID-19 patients.
This is a randomized controlled trial designed to evaluate the effect of dietary supplementation on endometriosis symptom remediation. Adolescent and young adults females aged 12 to 25 years with a surgically-confirmed diagnosis of endometriosis will be eligible for study participation. Subjects will be excluded if they have concurrent chronic illnesses that affect gastrointestinal absorption of nutrients (e.g., celiac disease, IBD, cystic fibrosis), a history of renal stones, are pregnant, or non-English speaking. Once consented, subjects will be randomized to one of 3 treatment assignments: 1) vitamin D3 2000 IU daily (n=30), 2) fish oil 1000 mg daily (n=30), 3) placebo (n=30) and will take these daily for 6 months. Baseline nutrient intake from food and supplements will be assessed using the Food Frequency Questionnaire (FFQ). The 142 item survey assesses usual dietary intake during the past year. Validated rating scales including the visual analog scale (VAS), SF-36, and the World Endometriosis EPHect questionnaires will be used to measure pain and overall quality of life. The SF-36 measures 8 health concepts relevant across disease groups, including limitations to physical or social activities because of health problems, vitality, and general health perception. Patients will complete a full review of medication usage, past medical history, family history, and other lifestyle factors. Anthropometrics will be measured, and vital signs obtained. Measures will be repeated at 3-month intervals for a total of 6 months. Blood will be drawn at baseline, and at 6 months to measure levels of fatty acids, vitamin D, parathyroid hormone (PTH), and calcium.
This will be a double-blind (neither physician nor the volunteer knowns whether placebo or active drug is administered), placebo-controlled, randomized (study drug is assigned by chance), 2-way crossover (the same procedure is repeated twice so that the volunteer receives placebo as well as active drug) study in cohorts of a maximum of 16 healthy male volunteers each, to investigate the effect of JNJ 40411813 or placebo on ketamine-induced psychosis-like symptoms. In the first cohort (Cohort 1), JNJ 40411813 effects at a dose level of 500 mg will be evaluated at the time of maximal plasma concentrations. If JNJ 40411813 significantly reduces psychotic symptoms relative to placebo, a second cohort (Cohort 2) will be initiated to investigate the effects of JNJ 40411813 at 24 hours following dose administration. If Cohort 1 shows no relevant effects of JNJ 40411813 the study will be stopped. If there are no relevant effects of JNJ 40411813 on the psychotic symptoms at 24 hours after dosing, a third cohort (Cohort 3) will be initiated to investigate the effects at 12 hours after dosing. If there are relevant effects of JNJ 40411813 at 24 hours after dosing, a fourth cohort (Cohort 4) following the same procedures as Cohort 1, will be initiated to investigate the effects at peak plasma concentration using a lower dose of JNJ 40411813. Volunteers will be randomly assigned in a crossover procedure to one of two sequences (JNJ 40411813/placebo or placebo/ JNJ 40411813) on Day -1 of the first study period of each cohort. At peak plasma level (Cohorts 1 and 4), 24 hours (Cohort 2) or 12 hours (Cohort 3) after dosing volunteers will receive ketamine as an infusion (i.e. directly into the vein) over 60 minutes. The ketamine administration will be preceded by a saline infusion over 90 minutes. Tests on the psychological function of the volunteers will be performed during and after saline and ketamine infusion. Safety assessments include daily ECG and vital signs, clinical laboratory assessments at the start and end of each study period, pulse oximetry (measurement of the oxygen content of the blood ) during each ketamine infusion and continuous Adverse Event Reporting. The study will be double blind for oral JNJ-40411813 or placebo, but open label (everyone knows the identity) for the IV administration of saline and ketamine. JNJ-40411813: 500 mg single oral dose or lower or matching placebo. Ketamine: continuous intravenous infusion of 0.005 mg/kg/min over 60 minutes.
A drug for treating bedsore is prepared from the following medicinal materials by weight: 5-15 g of roasted dragon bone powder, 20-50 g of Yunnan Baiyao powder and 30-60 ml of 75% alcohol. The method for preparing the drug provided by the invention comprises evenly mixing the roasted dragon bone powder with the Yunnan Baiyao powder and the alcohol to form paste for future use. According to the traditional Chinese medicine for treating bedsore and the traditional Chinese medicine components of the preparation method, the roasted dragon bone powder, the Yunnan Baiyao powder and the 75% alcohol combined with each other, are capable of healing, promoting tissue regeneration, promoting blood circulation and eliminating stagnant blood, and discharging pus to heal. The drug is pure traditional Chinese medicine preparation and has no toxic and side effect; and generally, most people can be cured except for individual patients who cannot insist treatment or delays treatment. The method of applying the drug comprises the following steps of: in treatment, also using hydrogen peroxide to thoroughly clean the surface of the bedsore and irradiating the bedsore by a far infrared ray therapeutic apparatus for 20 minutes; and then applying the drug provided by the invention to the surface of the bedsore by a thickness of 1.4-4 mm, and additionally, wrapping the bedsore with external sterilized dressing. Besides, the dressing should be changed twice each day.
Participants in the control arm receive usual care. In this case they receive naloxone training only. The training involves a 1-hour in-person overdose recognition and reversal course, which addressed the following topics: the scope and nature of the opioid overdose epidemic nationally and locally in Philadelphia, signs of opioid overdose, strategies for approaching or interacting with a person who is suspected to have overdosed, administration of naloxone in its nasal spray formulation, what to expect after administering naloxone, legal considerations and Good Samaritan protection, and how and where to acquire naloxone.
Albuterol tablets contain albuterol sulfate USP, the racemic form of albuterol and a relatively selective beta 2-adrenergic bronchodilator. Albuterol sulfate has the chemical name α 1-[( tert-butylamino)methyl]-4-hydroxy- m-xylene- α,α-diol sulfate (2:1) (salt) and the following structural formula: 

Albuterol sulfate has a molecular weight of 576.7, and the molecular formula is (C 13H 21NO 3) 2\. H 2SO 4. Albuterol sulfate, USP is a white or almost white crystalline powder, freely soluble in water, practically insoluble or very slightly soluble in Methylene chloride and alcohol, slightly soluble in Chloroform and Ether. 

The World Health Organization recommended name for albuterol base is salbutamol.

Each albuterol tablet for oral administration contains 2 mg or 4 mg of albuterol as 2.4 mg or 4.8 mg of albuterol sulfate USP, respectively. Each tablet also contains the following inactive ingredients: anhydrous lactose, hypromellose, magnesium stearate and sodium starch glycolate.
The invention discloses a medicament compound adopting bicyclo-ethanol as an active component and a preparation thereof. The medicament compound is formed by dissolving the bicyclo-ethanol in a medicament carrying substance consisting of one or more of surfactant, cosurfactant and oils, and is in the form of an oily solution or a semisolid object at room temperature. Through different formulas, the medicament compound can form emulsion and microemulsion quickly through gentle agitation. After being taken orally, the medicament compound can be used for enhancing the bicyclo-ethanol absorption of insoluble medicaments through self-emulsification and self-microemulsification, reducing the individual differences, and improving the bioavailability and clinical effects of the bicyclo-ethanol. The medicament compound is simple in preparation technology and is suitable for being prepared into various preparations. The invention further discloses a hard capsule, a soft capsule, a slow control and release type capsule, an osmotic pump type capsule and other suitable preparations, which are made from the medicament compound.
A method is disclosed for obtaining an organic solution of paclitaxel by way of novel purification technology. The method uses a "Load and Lock Axial Compression Column" for industrial scale preparative high performance liquid chromatography. The "Load and Lock Axial Compression Column" is one in which a piston is used to pack and unpack the chromatography bed substantially to avoid voids therein, and to maintain bed compression during use. This maintenance of the compression effectively and substantially prevents the formation of voids in the bed, which increases the efficiency of the procedure. The column can be packed with any packing material, including small particle size (e.g., about 10 µm) media. In this way, very high plate numbers are generated. The bed length can be adjusted by controlling the amount of packing material used to prepare the column. Additional steps enable paclitaxel to be isolated with a purity of 99% or more, and for crystalline 9-dihydro-1,3-acetylbaccatin III to be isolated for use in medicaments.
BACKGROUND: Alcohol withdrawal syndrome (AWS) is associated with increased morbidity and mortality in the trauma population. Benzodiazepines (BZDs) are standard of care for AWS; however, given the risk of delirium with BZDs and reports of BZD-refractory withdrawal, phenobarbital (PHB) has emerged as an alternative therapy for AWS. Safety and efficacy studies of PHB for AWS in trauma patients are lacking. Our aim was to compare a BZD versus PHB protocol in the management of AWS in trauma patients.
METHODS: We performed a retrospective cohort study at a level 1 trauma center of patients at risk for AWS managed with either a BZD or a low-dose oral PHB regimen. Patients were excluded if they were taking BZDs or barbiturates before admission, received propofol or dexmedetomidine before initiation of the study drug, presented with delirium tremens or seizures, or died or discharged within 24 hours of presentation. The primary outcome was complicated AWS (seizures or alcohol withdrawal delirium/delirium tremens). Secondary outcomes included uncomplicated AWS; therapy escalation; oversedation; delirium-, intensive care unit-, and ventilator-free days; and length of stay.
RESULTS: A total of 411 patients were identified; 118 received BZD, and 293 received PHB. The odds of developing complicated AWS with PHB versus BZD-based therapy were not statistically significant (odds ratio [OR], 0.52; 95% confidence interval [CI], 0.21-1.39); however, patients receiving PHB were less likely to develop uncomplicated AWS (OR, 0.08; 95% CI, 0.04-0.14) and less likely to require escalation of therapy (OR, 0.45; 95% CI, 0.24-0.84). The PHB group had a length of stay 3.1 days shorter than the BZD group ( p = 0.002). There was no difference in intensive care unit-, ventilator-, or delirium-free days.
CONCLUSION: A PHB-based protocol for the management of AWS is a safe and effective alternative to BZD-based regimens in trauma patients.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level IV.
Myocardial infarction (MI) has a 5-year mortality rate of more than 50% due to the lack of effective treatments. Interactions between cardiomyocytes and the MI microenvironment (MIM) can determine the progression and fate of infarcted myocardial tissue. Here, a specially designed Melanin-based composite nanomedicines (MCN) is developed to effectively treat MI by reprogramming the MIM. MCN is a nanocomposite composed of polydopamine (P), Prussian blue (PB) and cerium oxide (CexOy) with a Mayuan-like structure, which reprogramming the MIM by the efficient conversion of detrimental substances (H+, reactive oxygen species, and hypoxia) into beneficial status (O2 and H2O). In coronary artery ligation and ischemia reperfusion models of male mice, intravenously injecting MCN specifically targets the damaged area, resulting in restoration of cardiac function. With its promising therapeutic effects, MCN constitutes a new agent for MI treatment and demonstrates potential for clinical application.